University of Montana

ScholarWorks at University of Montana
Biomedical and Pharmaceutical Sciences Faculty
Publications

Biomedical and Pharmaceutical Sciences

2004

Fluorometric measurements of conformational
changes in glutamate transporters
H. Peter Larsson
Anastassios V. Tzingounis
Hans-Peter Koch
The University of Montana

Michael Kavanaugh
University of Montana - Missoula

Let us know how access to this document benefits you.
Follow this and additional works at: https://scholarworks.umt.edu/biopharm_pubs
Part of the Medical Sciences Commons, and the Pharmacy and Pharmaceutical Sciences
Commons
Recommended Citation
Larsson, H. Peter; Tzingounis, Anastassios V.; Koch, Hans-Peter; and Kavanaugh, Michael, "Fluorometric measurements of
conformational changes in glutamate transporters" (2004). Biomedical and Pharmaceutical Sciences Faculty Publications. 45.
https://scholarworks.umt.edu/biopharm_pubs/45

This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at ScholarWorks at University of Montana. It has
been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of ScholarWorks at
University of Montana. For more information, please contact scholarworks@mso.umt.edu.

Fluorometric measurements of conformational
changes in glutamate transporters
H. Peter Larsson*†, Anastassios V. Tzingounis‡, Hans P. Koch*, and Michael P. Kavanaugh†§
*Neurological Sciences Institute, Oregon Health & Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006; ‡Neuroscience Graduate Program,
Oregon Health & Science University, Portland, OR 97205; and §Center for Structural and Functional Neuroscience, Department of Biomedical and
Pharmaceutical Sciences, University of Montana, Missoula, MN 59812
Edited by H. Ronald Kaback, University of California, Los Angeles, CA, and approved January 15, 2004 (received for review October 31, 2003)

G

lutamate is the primary excitatory neurotransmitter in the
CNS. After its release from presynaptic terminals, glutamate diffuses rapidly across the synaptic cleft and activates
postsynaptic receptors. The concentration and lifetime of glutamate in the synaptic cleft are predominantly determined by the
amount of glutamate released, the geometry of the synaptic cleft,
and the number and localization of glutamate transporters with
respect to glutamate release sites (1, 2). The activity of glutamate
transporters also determines synapse independence and regulates the amount of glutamate reaching extrasynaptic receptors,
i.e., glutamate spillover (2). In addition, glutamate transporters
have been found to control ambient glutamate levels, thus setting
the lower limit of glutamate in the brain (3, 4) and preventing
glutamate from reaching neuro-toxic levels (1). Glutamate
transporters possibly play a role in the progression and development of certain neurological disorders, such as amyotrophic
lateral sclerosis (ALS) and epilepsy (1). Glutamate transporters
have also been hypothesized to play an important role in
neuronal survival during ischemia (1).
The removal of glutamate from the extracellular milieu is
achieved by a family of excitatory amino acid transporters 1 to
5 (EAAT1 to -5) that are localized in glial cells and neurons (5,
6). The uptake of one glutamate molecule is coupled to the
uptake of three Na⫹ ions and one proton, and the extrusion of
one K⫹ ion (3, 7). The large electrochemical gradients for Na⫹
and K⫹ provide the driving force for glutamate uptake against
its gradient (3). The proton has been hypothesized to play a
neuro-protective role during ischemia by shutting down reverse
uptake of glutamate (8), but the exact mechanism by which the
proton reduces reverse transport is unclear. Although the imwww.pnas.org兾cgi兾doi兾10.1073兾pnas.0306737101

portance of glutamate transporters in synaptic transmission and
pathophysiology (e.g., ischemia) is well established, little is
known about the molecular structure of glutamate transporters
and the conformational changes that occur when glutamate is
removed from the extracellular space. In addition, it is controversial as to how the different cosubstrates are coupled to the
transport of glutamate (3, 9).
Several approaches have been used to probe conformational
changes associated with glutamate transport. For example,
Grunewald and Kanner (10) compared how trypsin cleaves the
glial transporter GLT-1兾EAAT2 in the presence and absence of
substrates. By using antibodies raised against different parts of
the transporter, they showed that trypsin cleaves the transporter
into different sets of fragments when the transporter is incubated
in transportable substrates (Na⫹, K⫹, glutamate) compared with
when it is incubated in nontransportable substrates (Li⫹, dihydrokinate), suggesting that the transported substrates induce
conformational changes that expose additional trypsin sites.
More recently, several groups have measured the accessibility of
cysteine-specific reagents to cysteines introduced at different
sites in glutamate transporters (11–14). By using this approach,
these groups have mapped the topology of the transporters and
also reported the accessibility of the studied cysteines in the
absence and presence of substrates (11–15). They showed that a
number of residues display substrate-dependent accessibility.
However, it is unknown whether the accessibility changed as a
result of a substrate-induced conformational change or whether
the substrate directly protected the cysteine from the cysteinespecific reagent.
In the present work, we used voltage clamp fluorometry
(VCF) to directly monitor the conformational rearrangements
associated with glutamate transporters in real time (for review,
see ref. 16). This technique was originally used to study conformational changes in potassium channels during the gating process (17, 18). More recently, VCF was also used in the study of
glucose transporters (19, 20), ␥-aminobutyric acid (GABA)
transporters (21), serotonin transporters (22), and Na⫹-K⫹
pumps (23). VCF was developed on the finding that a fluorophore is sensitive to its local environment. Therefore, when a
conformational change occurs in response to a stimulus (e.g., a
change in membrane potential), the environment around the
fluorophore may also change. Such an environmental change is
reported as either an increase or decrease of the fluorescence
signal (16). The advantage of VCF over conventional electrophysiological recording techniques (24, 25) and biochemical
assays (11–14) is that VCF allows for the monitoring of real-time
protein conformational changes, even if the conformational
changes are electro-neutral.
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: EAAT, excitatory amino acid transporter; VCF, voltage clamp fluorometry;
TBOA, DL-threo-␤-benzyloxyaspartate; pHo, external pH.
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Glutamate transporters remove glutamate from the synaptic cleft
to maintain efficient synaptic communication between neurons
and to prevent extracellular glutamate concentrations from reaching neurotoxic levels (1). It is thought that glutamate transporters
mediate glutamate transport through a reaction cycle with conformational changes between the two major access states that
alternatively expose glutamate-binding sites to the extracellular or
to the intracellular solution. However, there is no direct real-time
evidence for the conformational changes predicted to occur during
the transport cycle. In the present study, we used voltage-clamp
fluorometry to measure conformational changes in the neuronal
excitatory amino acid transporter (EAAT) 3 glutamate transporter
covalently labeled with a fluorescent reporter group. Alterations in
glutamate and cotransported ion concentrations or in the membrane voltage induced changes in the fluorescence that allowed
detection of conformational rearrangements occurring during forward and reverse transport. In addition to the transition between
the two major access states, our results show that there are
significant Naⴙ-dependent conformational changes preceding glutamate binding. We furthermore show that Naⴙ and Hⴙ are
cotransported with glutamate in the forward part of the transport
cycle. The data further suggest that an increase in proton concentrations slows the reverse transport of glutamate, which may play
a neuro-protective role during ischemia.

CaCl2, and 1 mM MgCl2 (pH 7.5). The data are reported as
mean ⫾ SE.

Fig. 1. Fluorescent measurements report on conformational changes related to glutamate transport. (A) Transmembrane topology of EAAT3, showing the location of A430C that was labeled with Alexa546-maleimide. (B and
C) Confocal image of the oocyte membrane, showing the fluorescence from
WT EAAT3 (B) and A430C (C) transporters labeled with Alexa546-maleimide.
The fluorescence measured at the membrane was ⬎30-fold higher for 430C
transporters than for WT transporters: F430C ⫽ 51.4 ⫾ 12.4 (n ⫽ 3) and FWT ⫽
1.7 ⫾ 0.4 (n ⫽ 3). (D) Parallel fluorescence and current measurements of a
representative oocyte during an application of 1 mM L-glutamate, 1 mM
L-glutamate plus 100 M TBOA, and 100 mM choline. Vm ⫽ ⫺80 mV. The
fluorescence baseline (before glutamate application) was ⬎10-fold higher
than the fluorescence from uninjected control oocytes. (E) Fluorescence and
current measurements during an application of 1 mM L-glutamate in 100 mM
choline or in 100 mM NaCl. Vm ⫽ ⫺80 mV.

In this study, we detected and measured glutamate transporter-specific conformational changes by introducing a cysteine at
position A430 (Fig. 1A) in the EAAT3 transporter (26) and
subsequently labeling it with an environmentally sensitive fluorescent probe. We found that the substrates L-glutamate and
D-aspartate are capable of inducing conformational changes in
EAAT3. In addition, we show that there are conformational
changes associated with Na⫹ binding. Finally, we provide direct
evidence that protons are cotransported with Na⫹ through the
Na⫹-hemicycle and not, as was recently proposed, through the
K⫹-hemicycle (9).
Methods
Expression of cRNA in Xenopus laevis Oocytes. Cysteine mutagenesis

and mRNA synthesis were performed as described. Collagenasetreated, defolliculated stage IV-V oocytes were injected with 50
ng of RNA and were incubated at 8°C in ND96 (5 mM
Na兾Hepes, pH 7.5兾96 mM NaCl兾2 mM KCl兾1.8 mM CaCl2兾1
mM MgCl2). Oocytes were incubated at 18°C for 12–15 h before
experiments. Experiments were performed 3–7 days after
injection.
Electrophysiology. Currents were measured at 22–25°C by twoelectrode voltage clamping using a Geneclamp 500 amplifier
(Axon Instruments, Foster City, CA). Data acquisition was
performed with an Apple G4 computer by using a Digidata
acquisition board 1322A controlled with AXOGRAPH 4.1 (Axon
Instruments, Foster City, CA). Current and voltage traces were
monitored with the MACLAB 2E A兾D software (A. D. Instruments,
Milford, MA). The currents were low-pass filtered at 1 kHz and
digitized at 5 kHz. Microelectrodes were filled with 3 mM KCl
(resistances of ⬍2 M⍀), and recordings from voltage-clamped
oocytes were performed with constant perfusion of Ringer’s
solution with various concentrations of substrates. The Ringer’s
solution contained 5 mM Na兾Hepes, 98.5 mM NaCl, 1.8 mM
3952 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0306737101

Labeling of Oocytes and Fluorescence Measurements. Oocytes were
labeled for 60 min with 10 M of the fluorescent maleimide
probe, Alexa 546 (Molecular Probes), in Ringer’s solution.
Fluorescence changes were recorded under voltage clamp conditions, by using an inverted fluorescence microscope (Nikon
Diaphot) with a ⫻20 quartz objective and a P100S photomultiplier. The objective was focused on the animal pole, and
fluorescence was monitored through a rhodamine filter cube:
exciter, HQ545兾⫻30; dichroic, Q570LP; and emitter, HQ620兾
60m. Fluorescence signals were low-pass filtered at 200–500 Hz
and digitized at 1 kHz. Fluorescence traces were monitored with
the MACLAB 2E A兾D software (A. D. Instruments). To control for
direct effects of the different substrates on the fluorescent probe,
Alexa 546-succinimyl-ester fluorophores were attached to glass
coverslips coated with polylysine. The emissions from these
fluorophores were measured in the same solutions that were
used to study the fluorescent-labeled transporters. The change
in fluorescence was very small in response to application of the
different solutions. The largest change was seen when switching
from a Na⫹-containing to a choline-containing solution
(⬍0.5%), indicating very small direct effects of the solutions on
the fluorescent probes.
Modeling. Computer simulations were made with BERKELEY

(www.berkeleymadonna.com) by using a previously
developed 15-state model for EAAT transporters (16, 27, 28).
Fluorescence intensities were assigned to the 15 different states
and fit to the steady-state fluorescence data. Several rates in an
earlier model were altered to better fit the fluorescence data.
The rates and the voltage dependence of the rates in the model
(see Fig. 4A) were chosen so that two elementary charges are
moved during one uptake cycle (3) and so that detail balance is
maintained (29), as in the following equation: f1f2f3 . . .f15兾b1b2b3
. . . b15 ⫽ exp(⫺⌬Gcycle兾RT), where fi and bi are the forward and
backward rates for the ith transition in the cycle, and ⌬G is the
total free-energy change during one cycle.

MADONNA

Results
EAAT3 Labeling and Fluorescence Measurements. We used site-

directed mutagenesis to introduce a cysteine at position A430 in
the neuronal glutamate transporter subtype EAAT3 (Fig. 1 A).
A430 is located in the extracellular loop between transmembrane
domains VII and VIII. This region is believed to be important
for glutamate binding and transport (for review, see ref. 30).
After labeling with the fluorescent probe Alexa-546-maleimide,
oocytes expressing A430C transporters exhibited a much higher
level of fluorescence than did oocytes expressing WT EAAT3
transporters (Fig. 1 B and C). This finding demonstrates that the
labeling of endogenous membrane proteins, as well as native
EAAT3 cysteines, does not contribute significantly to the observed fluorescent signals. As a result, it was not necessary to use
a cysteine-less EAAT3.
We established the functionality of the labeled transporter by
measuring glutamate-evoked currents (Fig. 1D) as well as uptake
of radioactively labeled glutamate (data not shown). Fig. 1D
shows a simultaneous recording of currents and the fluorescence
emission of Alexa-546-labeled A430C. The addition of 1 mM
glutamate induced a current that was accompanied by a fluorescence decrease (Fig. 1D). The competitive transporterblocker DL-threo-␤-benzyloxyaspartate (TBOA) (31, 32) inhibited both the glutamate-activated current and the fluorescence
change, suggesting that the fluorescence change was due to
conformational rearrangements in the glutamate transporter
(Fig. 1D). Fluorescence changes with the opposite polarity were
seen when extracellular Na⫹ was replaced with choline (Fig. 1D).
Larsson et al.

Fig. 2. Voltage- and substrate-dependence of A430C fluorescence. (A) Fluorescence in response to voltage steps from ⫺200 mV to ⫹200 mV (in increments of
⫹20 mV), from a holding potential of ⫺30 mV, in 100 mM Na⫹ (upper trace) and 100 mM choline (lower trace). Each trace is the average of four identical sweeps.
(B and C) Voltage-dependence of the steady-state fluorescence changes (⌬F-V) in the presence of different substrates. The fluorescence acquired at ⫺30 mV (in
100 mM Na⫹) was set as 0. The data were fitted to a Boltzmann function with V0.5 ⫽ 33.1 ⫾ 5 mV, zd ⫽ 0.34 ⫾ .013 (n ⫽ 11) for 1 mM glutamate; V0.5 ⫽ 75.1 ⫾
21.1 mV, zd ⫽ 1.3 ⫾ .7 (n ⫽ 6) for 1 mM D-aspartate; V0.5 ⫽ 17.9 ⫾ 4.0, zd ⫽ 0.45 ⫾ .04 (n ⫽ 4) for 100 mM K⫹; and V0.5 ⫽ ⫺5.6 ⫾ 2.5 mV, zd ⫽ 0.41 ⫾ .0085 (n ⫽
22) for 100 mM Na⫹.

Voltage Dependence of the Fluorescence Signal. To better understand the molecular mechanisms responsible for the changes in
the fluorescence signals, we studied the effects of changing the
membrane voltage under different ionic and substrate conditions. Previously, glutamate transporters were found to generate
Na⫹-dependent transient currents in response to changes in the
membrane voltage (25, 33). These transient currents were interpreted as being due to Na⫹ binding to sites located within the
electric field where changes in membrane potential shift the
distribution of transporters between the Na⫹-unbound and
Na⫹-bound states (25, 33).
In 100 mM NaCl, the fluorescence emissions from labeled
A430C increased during steps to positive voltages but decreased
during steps to negative potentials (Fig. 2A). The steady-state
fluorescence vs. voltage data were well fitted by a single Boltzmann curve with zd ⫽ 0.41 ⫾ .0085 (n ⫽ 22) and V05 ⫽ ⫺5.6 ⫾
2.5 mV (n ⫽ 22) (Fig. 2B). These values are similar to those for
EAAT2, zd ⫽ 0.41 ⫾ .07 and V05 ⫽ 3.2 ⫾ 0.2 mV (n ⫽ 19), (25)
and EAAT3 transient currents, zd ⫽ 0.35 ⫾ .02 and V05 ⫽
⫺26.7 ⫾ 0.4 mV (n ⫽ 4), suggesting that the transient currents
and the fluorescence changes are due to the same process. Our
data suggest that the highest fluorescence state occurs when the
transporter is Na⫹-unbound whereas the fluorescence decreases
when Na⫹ binds to the transporter. Choline cannot replace Na⫹
as a cosubstrate for glutamate uptake (25), and, as a result, the
transporter should always be in a Na⫹-unbound state in a choline
solution, regardless of the membrane potential. Consistent with
this hypothesis, we found that the fluorescence in the presence
of choline increased to the same level as in Na⫹ at ⫹200 mV
where the Boltzmann function predicts 97% of transporters to be
in the Na⫹-unbound state (Fig. 2 A and B). Furthermore, we found
the fluorescence in choline to be voltage-independent. In the
presence of high-external K⫹, which induces reverse transport of
endogenous glutamate in the oocyte (3), we found the steady-state
fluorescence vs. the voltage data to have the opposite voltage
dependence from the voltage dependence in Na⫹ (Fig. 2C).
The application of glutamate or aspartate decreased the
fluorescence at all voltages tested, suggesting that, during transLarsson et al.

port, the steady-state distribution of conformational states is
shifted compared with that in Na⫹, such that higher fluorescence
states are less populated (Fig. 2C). In addition, the fluorescence
is decreased below the fluorescence level reported in high Na⫹
concentrations at very negative voltages, suggesting that the
transportable amino acids induce a conformational change that
further decreases the fluorescence (Fig. 2C). In the continuous
presence of glutamate, the transporters will spend a large
proportion of time in the state preceding the rate-limiting step
in the cycle, which is believed to be the K⫹-extrusion step (27,
28). Therefore, in the presence of glutamate, we hypothesize that
the transporter will spend most of the time with its binding sites
exposed to the cytosolic solution. Our results suggest that this
state(s) represents a molecular conformation that is different
from those with binding sites exposed to the extracellular
solution and that this molecular conformation has the lowest
fluorescence level.
Naⴙ and Liⴙ Dependence of the Fluorescence Signals. We next

characterized in detail the steps preceding the binding of glutamate. Our fluorescence data are in agreement with previous
work suggesting that at least one Na⫹ binds before glutamate
(25, 34). The data presented in the previous section suggest that,
in the absence of glutamate, the fluorescence emission changes
in parallel to the Na⫹ occupancy of the transporter. Therefore,
we measured the cation dependence of the fluorescence signal
(Fig. 3A). In Fig. 3B, the voltage dependence for a steady-state
fluorescence signal (⌬F-V) at different Na⫹ concentrations is
shown. Changes in the Na⫹ concentration did not affect the slope
of the curves, but rather shifted the midpoint of the curves: at
higher Na⫹ concentrations, the ⌬F-V curves were shifted to
depolarized potentials, and, at lower Na⫹ concentrations, the
⌬F-V curves were shifted to hyperpolarized potentials (Fig. 3B).
These shifts of the ⌬F-V curve as a function of the Na⫹
concentration are consistent with the hypothesis that the fluorescence change monitors the Na⫹ occupancy of the transporter.
For any specific voltage, at higher Na⫹ concentrations, more
transporters will have bound Na⫹, and, at lower Na⫹ concentrations, fewer transporters will have bound Na⫹.
Until recently, it was believed that only extracellular Na⫹ ions
could support amino acid transport through the EAATs, even
though lithium was found to replace at least one Na⫹ in GLT-1
(10). Borre and Kanner (35) demonstrated that, in EAAC1 (the
rabbit homologue of EAAT3), L-aspartate induces steady-state
currents in the presence of Li⫹, suggesting that Li⫹ replaces Na⫹
at all Na⫹-binding sites in EAAT3. They showed that Li⫹
PNAS 兩 March 16, 2004 兩 vol. 101 兩 no. 11 兩 3953
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In addition, the glutamate-induced fluorescence changes were
abolished when extracellular Na⫹ was replaced with choline (Fig.
1E), suggesting that at least one Na⫹ binds before glutamate.
The Na⫹ dependence and the inhibition by TBOA of the
fluorescence changes indicate that the changes in the fluorescence signals are directly related to the glutamate transporter
and not to other proteins endogenous to the oocytes.

Fig. 3. Voltage dependence of fluorescence in the presence of different cation and proton concentrations. (A) Representative fluorescence traces from the
same oocyte following voltage steps (⫺200 mV to ⫹200 mV; increments of 20 mV) in the presence of 25 mM Na⫹ (upper trace) or 200 mM Na⫹ (lower trace),
from a holding potential of ⫺30 mV. (B) ⌬F-V measured in the presence of extracellular Ringer’s solution containing either 100 mM Li⫹ (V0.5 ⫽ ⫺65.245 ⫾ 4.93
mV, zd ⫽ 0.359 ⫾ .014, n ⫽ 4), 25 mM Na⫹ (V0.5 ⫽ ⫺40.3 ⫾ 6.8 mV, zd ⫽ 0.35 ⫾ .023, n ⫽ 5), 100 mM Na⫹ (V0.5 ⫽ ⫺5.6 ⫾ 2.5 mV, zd ⫽ 0.41 ⫾ .0085, n ⫽ 22), and
200 mM Na⫹ (V0.5 ⫽ 46.9 ⫾ 6.97 mV, zd ⫽ 0.376 ⫾ .011, n ⫽ 4). To avoid any issues with osmolarity during measurements, the total cation concentration was
set to a constant of 200 mM by the appropriate addition of choline. (C) ⌬F-V measured at external pH (pHo) 8.5, pHo 7.5, and pHo 6.5 in 100 mM Na⫹. The data
were normalized to the maximum response at each pHo. The data were fitted to a Boltzmann function with V0.5 ⫽ ⫺56.4 ⫾ 6 mV (n ⫽ 11) and zd ⫽ 0.42 ⫾ 0.03
(n ⫽ 11) for pHo 8.5, V0.5 ⫽ ⫺12.1 ⫾ 3 mV (n ⫽ 15) and zd ⫽ 0.42 ⫾ 0.0009 (n ⫽ 15) for pHo 7.5, and V0.5 ⫽ 19.2 ⫾ 0.01 (n ⫽ 10) and zd ⫽ 0.42 ⫾ 0.01 (n ⫽ 10)
for pHo 6.5. ⌬F-V curves indicate that at ⫺80 mV at pHo 7.5, 80% of the transporters were Na⫹- and proton-bound.

supports steady-state currents, although significantly smaller in
magnitude than in Na⫹. To test whether Li⫹ and Na⫹ bind with
the same affinity to EAAT3, we compared the Na⫹-induced
fluorescence changes to those induced by Li⫹. Fig. 3B shows that,
in the presence of Li⫹, the ⌬F-V curve shifts to the left without
changing its slope. In particular, the ⌬F-V curve in 100 mM Li⫹
shifts to even more hyperpolarized voltages than the ⌬F-V curve
in 25 mM Na⫹. This finding suggests that Li⫹ binds to the same
cation-binding sites and induces the same conformational
changes as does Na⫹, but with an ⬇5- to 10-fold lower affinity.
Proton Dependence of the Fluorescence Signals. In addition to being
coupled to the transmembrane movements of Na⫹ and K⫹,
glutamate transport in EAATs is also coupled to the transmembrane movement of protons. However, it has not been resolved
whether protons are transported through the Na⫹-hemicycle (3,
27, 28, 36) or through the K⫹-hemicycle (9). We addressed this
issue by measuring the proton dependence of the fluorescence
changes in the glutamate transporter. Recently, we developed a
kinetic model for glutamate transporters (27, 28) and proposed
that protons bind immediately before or after glutamate. In this
model, or in a model where proton binding precedes glutamate
binding, a change in the extracellular proton concentration
should, by mass action, shift the ⌬F-V similarly to a change in the
extracellular Na⫹ concentration. If, on the other hand, protons
are either predominantly bound after glutamate (3) or in the
K⫹-hemicycle (9), we should observe no shift in the ⌬F-V curve
in the absence of extracellular K⫹ and glutamate.
The steady-state fluorescence vs. voltage was measured in 100
mM NaCl at pH 6.5, 7.5, and 8.5. Changes in the concentration
of pH shifted the ⌬F-V curves along the voltage axis. When the
proton concentration was decreased to pH 8.5, the ⌬F-V curve
shifted to the left. Conversely, the ⌬F-V shifted to the right when
the pH was lowered to 6.5 (Fig. 3C). The decrease or the increase
in proton concentration shifted the ⌬F-V curve in the same
direction as did the similar changes in the Na⫹ concentration,
indicating that protons and Na⫹ bind in the same part of the
transport cycle (3, 27, 28, 36).

Discussion
In this study, we have used VCF to study conformational changes
in the neuronal glutamate transporter EAAT3. The fluorescentlabeled A430C transporter displayed a decrease in fluorescence
in response to the application of external glutamate. The fluo3954 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0306737101

rescence change was partly inhibited by the transporter-blocker
TBOA. The substrate-induced fluorescence changes were voltage- and Na⫹-dependent. In addition, in the absence of external
amino acids, the fluorescence changed in response to changes in
membrane voltage. These fluorescence changes were also Na⫹dependent. The fluorescent-labeled A430C transporter used in
this study was fully functional.
The fluorescence changes in response to different substrates
or voltage steps imply that the transporter undergoes conformational changes, resulting in a change in the environment that
the fluorophore senses. Earlier models have assumed that there
are two major conformational changes that occur during glutamate transport (37): a transition of the binding sites in the
glutamate-bound transporters from outside to inside, and a
transition of binding sites in the K⫹-bound transporters from
inside to outside. However, until now, very little direct evidence
for such structural rearrangements has been reported. Our data
show that there are conformational changes in response to
glutamate binding. In addition, our data show that an additional
conformational change occurs in response to Na⫹ binding
because fluorescence changes are detected in response to voltage steps even in the absence of external glutamate and K⫹.
To better understand the molecular mechanisms underlying
these fluorescence changes, we modeled the fluorescence data
by using a kinetic model (Fig. 4A) that we have recently
developed for EAAT3 (16, 27) and EAAT2 (28), as well as for
EAAT1 and EAAT4 (27). To fit the fluorescence data, we made
a few minor modifications to the earlier model, which had no
effect on any of our previous conclusions (27, 28). The charge
valences for Na⫹ and proton binding were decreased (Fig. 4A),
and the extracellular Na⫹ affinity for the first two Na⫹-binding
sites was altered by a factor of 2.5. We simulated the steady-state
fluorescence data (Fig. 4 B–D) by assigning one of three
fluorescence intensities to the different transporter states (where
the fluorescence is given as the percentage of change from the
fluorescence in our reference condition, which is defined as ⫺30
mV in the presence of 100 mM NaCl in the absence of glutamate): To and ToK each have a fluorescence value of 2.4 whereas
the remaining extra- and intracellular states have values of ⫺1.24
and ⫺4, respectively. Three fluorescence intensity levels in a
cyclic model indicated that at least three conformational changes
occur during one transport cycle. The model qualitatively simulated the ⌬F-V in (i) Na⫹, K⫹, choline, and glutamate (Fig. 4B),
(ii) the Na⫹ dependence of the ⌬F-V (Fig. 4C), and (iii) the
Larsson et al.

Fig. 4. An EAAT3 model with only three conformational changes simulates
our experimental findings. (A) A modified 15-state model (16, 28) used to
simulate the fluorescence data. The steady-state fluorescence data are well
described by the 15-state model, after assigning three fluorescence intensities
(2.4, 1.24, and ⫺4) to the different states indicated by the dashed boxes. (B)
Simulation of ⌬F-V in different external solutions: 100 mM Na⫹ (E), 100 mM
choline (䊐), 100 mM K⫹ (‚), and 100 Na⫹ mM plus 1 mM glutamate (〫). (C)
Simulation of ⌬F-V in different external Na⫹ concentrations: 50 mM (E), 100
mM (‚), 200 mM (䊐) (pHexternal 7.5). (D) Simulation of ⌬F-V at different
external pH: pH 6.5 (䊐), pH 7.5 (〫), and pH 8.5 (E); Na⫹external ⫽ 100 mM. (E)
Simulated reverse transport current. The steady-state reverse transport current at 0 mV is plotted at different pH (both internal and external were altered
in parallel): K⫹internal ⫽ 50 mM, K⫹external ⫽ 50 mM, Na⫹internal ⫽ 25 mM,
Na⫹external ⫽ 25 mM, glutamateinternal ⫽ 10 mM, and glutamateexternal ⫽
0.1 mM.

proton dependence of the ⌬F-V (Fig. 4D). In the absence of
external glutamate or K⫹, the transporter is in states with binding
sites exposed to the external solution: states with relatively high
fluorescence in our model. The voltage dependence of the
fluorescence in the absence of glutamate and K⫹ is due to the
voltage dependence of Na⫹ binding and unbinding. The Na⫹bound states had a lower fluorescence value (⌬F ⫽ ⫺1.24)
compared with the empty transporter state (⌬F ⫽ 2.4), and,
hence, the fluorescence decreased at more negative potentials.
In the presence of glutamate, the transporter is mainly in states
with binding sites exposed to the intracellular solution: states
that have even lower fluorescence values (⌬F ⫽ ⫺4).
In the presence of high extracellular K⫹, the voltage dependence for the ⌬F-V was opposite to that in the presence of
extracellular Na⫹. In high external K⫹, EAATs have been shown
to reverse direction and expel glutamate from the cell, i.e., to
reverse glutamate transport (3, 38). During reverse transport,
our model suggests that most transporters are accumulated on
the external K⫹-bound state, partly due to the slow translocation
rates between ToK and TiK. We have previously suggested that
Larsson et al.

the transmembrane movement of ions associated with the K⫹bound transporters moves a net negative charge (27, 28). Therefore, as the membrane potential becomes more positive, the
transporters most likely move to states with binding sites exposed
to the intracellular solution: states that have a lower fluorescence
value (⫺4). Therefore, the model can explain the opposite
voltage-dependence of the fluorescence in high K⫹ compared
with Na⫹ as being due to the opposite charge associated with the
K⫹-translocation steps compared with the Na⫹-binding steps.
Our fluorescence data provide strong evidence that the transporter undergoes at least three major conformational changes
during a transport cycle. In addition to the two conformational
changes between the two major access states in which substrates
are translocated, the data also suggest that the binding of Na⫹
causes an additional conformational change because the Na⫹bound states have a much lower fluorescence than the empty
transporters. We hypothesize that Na⫹ binding is followed by a
conformational change that occludes Na⫹ within the protein
(29) (Fig. 5). Such occlusion events have been observed in
Na⫹-K⫹ ATPases (29, 39–41) and Ca2⫹ ATPases (29, 42), and
they have also been suggested as a mechanism for GABA
transporter-1 (GAT1) (43, 44). Also, the crystal structures of
H⫹-ATPase and Ca2⫹-ATPase suggest that such occlusion and
transport events require the rotational and translational movement of several helices (45, 46). For simplicity, we combined the
binding and occlusion events in our model. In this model, the
binding rate of a Na⫹ ion, instead of being diffusion-limited
(⬇108 to 109 s⫺1), had a significantly slower rate (⬇104 s⫺1). Such
a slow rate was also necessary to simulate the coupled current
kinetics in outside-out patches (28), suggesting that the coupled
charge movements are a combination of ion binding and occlusion events.
Although the thermodynamic coupling of protons to glutamate transport is widely accepted (3, 7), it is controversial
whether glutamate is transported through the Na⫹-hemicycle or
the K⫹-hemicycle. Zerangue and Kavanaugh (3, 36) have suggested that the proton is transported together with the Na⫹ ions,
based on the observation that the zwitterion L-cysteine is
transported without any internal acidification, contrary to the
transport of L-glutamate. Later experiments using rapid glutaPNAS 兩 March 16, 2004 兩 vol. 101 兩 no. 11 兩 3955
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Fig. 5. Molecular model of substrate-induced conformational changes in
EAAT3. Molecular schematic of the three conformational changes hypothesized in the 15-state model (Fig. 4A). A positive charge residue (marked by ⫹)
is assumed to quench the fluorescent probe attached to 430C. Na⫹ binding
induces a conformational change that reduces the distance between the
fluorescent probe and this quenching residue. The glutamate translocation
step induces an additional conformational change that further reduces the
distance between the fluorescent probe and this quenching residue.

mate concentration jumps supported this hypothesis (47). In
contrast, Auger and Attwell (9), studying the Purkinje neuron
transporter, proposed that a proton is exchanged with a potassium ion. They based this hypothesis on their finding that
changes in proton concentration did not drastically alter the
kinetics of the glutamate-activated current. Our data are consistent with the first hypothesis (Fig. 3), in which the protons are
transported through the Na⫹-hemicycle (3, 36). In contrast, our
data are not consistent with proton translocation in the K⫹hemicycle, for which changes in pH should not have any effect
on the ⌬F-V in the absence of K⫹ and glutamate. However, our
model does simulate the data of Auger and Atwell (9) (data not
shown and ref. 27). We also note that, if protons bind predominantly after glutamate, there would be no shifts in the ⌬F-V in
response to changes in the proton concentrations in the absence
of glutamate. Therefore, we conclude that, in physiological
solutions and before the application of glutamate, the transporters are already in a proton-bound state. This hypothesis is
consistent with our earlier model, in which the protons and
glutamate bind to EAATs in random order, and the affinity of
the transporters for protons is high (27, 28). Therefore, we
conclude that the vast majority of the transporters are in a
proton-bound state before the application of glutamate.
The question remains, however, as to why glutamate transport
is coupled to the H⫹ gradient. The thermodynamic value of
coupling the proton to glutamate uptake is mainly due to the
charge of the proton because there is only a relatively small
proton gradient. We propose that the protons also have a kinetic
effect rather than only a thermodynamic effect. It has been
suggested that the transporters initially act as a buffer by rapidly
binding glutamate, followed by a slower glutamate translocation
(33, 48, 49). To buffer glutamate efficiently, the transporters
must be in a state in which they can quickly bind glutamate.
However, before glutamate can bind to the transporters, Naⴙ
ions must also bind to the transporters (25, 27, 34). At low

concentrations of protons, a large number of transporters are
likely to be found in either To or ToNa1 states because the
apparent affinity for Na⫹ is only ⬇100 mM at 0 mV (25, 34). Our
model suggests that the true affinity for Na⫹ is only 250 mM at
0 mV (Fig. 4A). The binding of protons after Naⴙ ensures that
the transporters are in a glutamate-competent state as the
proton ‘‘locks’’ Na⫹ ions into their binding sites. Hence, during
physiological conditions, a majority of the transporters will be in
the ToNa2H state, ready to bind glutamate.
Such a kinetic effect of the proton has implications during
conditions such as ischemia. During ischemia, there is a collapse of
ion gradients (50), and the transporters reverse to reach the new
equilibrium dictated by the new ion gradients. It has been documented that the efflux of glutamate from the transporters, as they
reach the new equilibrium, has detrimental effects on brain physiology (1, 51, 52). However, for transient ischemia, the speed at
which the transporters reach this new equilibrium value is important. During ischemia, the extracellular and intracellular pH levels
decrease to as low as 6.5 (50). As a result, the transporters are driven
toward glutamate-bound states, in which case they act more like
glutamate exchangers than glutamate transporters. Simulations of
our model during ischemic conditions (low pH and collapsed Na⫹
and K⫹ gradients) show that lowering the pH slows the reverse
transport significantly (Fig. 4E). The net effect is a significant
slowing down of the rate at which the transporters reach the new
equilibrium and, therefore, a slowing down of the rise of extracellular glutamate concentrations (8). This hypothesis suggests that the
proton plays a neuro-protective role by slowing down the reverse
transport of glutamate during ischemia, and thus possibly protecting
neurons from excito-toxicity.
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Corrections

NEUROSCIENCE. For the article ‘‘Fluorometric measurements of
conformational changes in glutamate transporters,’’ by H. Peter
Larsson, Anastassios V. Tzingounis, Hans P. Koch, and Michael
P. Kavanaugh, which appeared in issue 11, March 16, 2004, of
Proc. Natl. Acad. Sci. USA (101, 3951–3956; first published
March 4, 2004; 10.1073兾pnas.0306737101), the authors note that,
due to a typographical error, several of the rates in Fig. 4A are
incorrect. The corrected figure and its legend appear below.

BIOPHYSICS. For the article ‘‘Preferred peptide backbone confor-

mations in the unfolded state revealed by the structure analysis
of alanine-based (AXA) tripeptides in aqueous solution,’’ by
Fatma Eker, Kai Griebenow, Xiaolin Cao, Laurence A. Nafie,
and Reinhard Schweitzer-Stenner, which appeared in issue 27,
July 6, 2004, of Proc. Natl. Acad. Sci. USA (101, 10054–10059;
first published June 25, 2004; 10.1073兾pnas.0402623101), the
authors note that ‘‘Trp’’ incorrectly appeared as ‘‘Try’’ in Fig. 2.
The corrected figure and its legend appear below.

Fig. 2. Representation of the dihedral angles obtained for the investigated
AXA peptides in the upper left square of the Ramachandran space. The
Zimmerman code was used to differentiate between the conformational
regions of extended ␤-strand and PPII. The dotted and solid vertical lines are
from the transition region discussed in the text.
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0404696101

Fig. 4. An EAAT3 model with only three conformational changes simulates
our experimental findings. (A) A modified 15-state model (16, 28) used to
simulate the fluorescence data. The steady-state fluorescence data are well
described by the 15-state model, after assigning three fluorescence intensities
(2.4, 1.24, and ⫺4) to the different states indicated by the dashed boxes. (B)
Simulation of ⌬F-V in different external solutions: 100 mM Na⫹ (E), 100 mM
choline (䊐), 100 mM K⫹ (‚), and 100 Na⫹ mM plus 1 mM glutamate (〫). (C)
Simulation of ⌬F-V in different external Na⫹ concentrations: 50 mM (E), 100
mM (‚), 200 mM (䊐) (pHexternal 7.5). (D) Simulation of ⌬F-V at different
external pH: pH 6.5 (䊐), pH 7.5 (〫), and pH 8.5 (E); Na⫹external ⫽ 100 mM. (E)
Simulated reverse transport current. The steady-state reverse transport current at 0 mV is plotted at different pH (both internal and external were altered
in parallel): K⫹internal ⫽ 50 mM, K⫹external ⫽ 50 mM, Na⫹internal ⫽ 25 mM,
Na⫹external ⫽ 25 mM, glutamateinternal ⫽ 10 mM, and glutamateexternal ⫽ 0.1 M.

host disease with retention of graft-versus-tumor effects by
the proteasome inhibitor bortezomib,’’ by Kai Sun, Lisbeth A.
Welniak, Angela Panoskaltsis-Mortari, Matthew J. O’Shaughnessy,
Haiyan Liu, Isabel Barao, William Riordan, Raquel Sitcheran,
Christian Wysocki, Jonathan S. Serody, Bruce R. Blazar,
Thomas J. Sayers, and William J. Murphy, which appeared
in issue 21, May 25, 2004, of Proc. Natl. Acad. Sci. USA
(101, 8120 – 8125; first published May 17, 2004; 10.1073兾
pnas.0401563101), the authors request that the following error
be noted. In the description of ‘‘In Vivo Studies’’ in Materials and
Methods, the dose of total body irradiation should have been
stated as 900 cGy for experiments performed at the University
of Nevada, Reno. The article inadvertently indicated the dose as
1,300 cGy. The dose range of 900–950 cGy for experiments
performed at the National Cancer Institute was correctly listed.
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0404699101

www.pnas.org兾cgi兾doi兾10.1073兾pnas.0404931101
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CORRECTIONS

IMMUNOLOGY. For the article ‘‘Inhibition of acute graft-versus-

